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Abstract
Objective: Autologous nonmyeloablative hematopoietic stem cell transplantation (AHST) was the first therapeutic approach
that can improve b cell function in type 1 diabetic (T1D) patients. This study was designed to investigate the potential
mechanisms involved.
Design and methods: We applied AHST to nine T1D patients diagnosed within six months and analyzed the acute
responses in peripheral blood for lymphocyte subpopulation as well as for genomic expression profiling at the six-month
follow-up.
Results: We found six patients obtained insulin free (IF group) and three remained insulin dependent (ID group); C-peptide
production was significantly higher in IF group compared to ID group. The acute responses in lymphocytes at six-month
follow-up include declined CD3
+CD4
+, CD3
+CD8
+ T cell population and recovered B cell, NK cell population in both groups
but with no significant differences between the two groups; most immune-related genes and pathways were up-regulated
in peripheral blood mononuclear cell (PBMC) of both groups while none of transcription factors for immune regulatory
component were significantly changed; the IF group demonstrated more AHST-modified genetic events than the ID group
and distinct pattern of top pathways, co-expression network as well as ‘hub’ genes (eg, TCF7 and GZMA) were associated
with each group.
Conclusions: AHST could improve the islet function in newly diagnosed T1D patients and elimination of the islet specific
autoreactive T cells might be one of the mechanisms involved; T1D patients responded differently to AHST possibly due to
the distinct transcriptional events occurring in PBMC.
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Introduction
Type 1 diabetes (T1DM) is an organ specific autoimmune
disease, resulting from chronic immune attack against pancreatic
beta cells [1]. Although it is thought to be mediated mainly by T
helper 1 cells, a complex interaction of immune cells including
CD4
+T cell, CD8
+Tcell and innate immune cell NK cell, B cell
and antigen presentation cell is actually involved in the
pathogenesis [2]. This course of immune-destruction is subclinical
until approximately 60% to 80% of the beta-cell mass is destroyed,
when the amount of beta-cell mass is insufficient to maintain
glucose homeostasis and the clinical diagnosis of T1DM is
established [3]. The best-established treatment is to tightly control
the blood glucose by intensive insulin therapy [4]. However, long-
term substitutive insulin therapy is still associated with major
constraints and lack of effectiveness in preventing chronic vascular
and neurological complications. Immunointervention therapy,
which targets the causal pathogenic mechanism, therefore, may
represent the only sensible strategy. Clinical trial of immunosup-
pression drugs (cyclosporine), antigen therapy (GAD) or immuno-
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patients with T1DM, however obstacles such as adverse effects,
lack of long-lasting improvement and especially the exogenous
insulin requirement remain still as a medical challenging [5].
In 2007, Julio C. Voltarelli’s group reported the first clinical
trial using AHST as a potential approach in cases of T1D [6].
Indeed, for the first time these studies demonstrated that AHST
led to prolonged insulin independence coupled with a significant
increase of c-peptide production. A follow-up study published two
years later confirmed the insulin independence was due to
improved b cell function instead of a prolonged honeymoon [7].
Therefore, AHST has been the only T1D-related management
shown to preserve b cell function. However, AHST requires a
relatively aggressive immune-intervention and complications such
as pneumonia and endocrine dysfunction have been noted.
Therefore, a need exists to be able to target those patients who
will receive the most benefit from AHST and to further clarify the
mechanisms involved in b cell function recovery so that the
strategy can be optimized and a broader patient population can
benefit from this treatment approach.
In this study, we applied AHST therapy to a group of nine
patients with newly diagnosed T1D and specifically investigated
their immune reconstitution, as well as performed transcriptome
profiling on their PBMC pre-treatment and six months post-
treatment to identify the acute responsive events, which might give
helpful insights to clarify the therapeutic mechanisms.
Methods
Patient management
Nine subjects diagnosed as T1D within six months by clinical
findings and hyperglycemia and confirmed with positive antibodies
against glutamic acid decarboxylase (GAD) [8] were enrolled from
January 2009 to December 2009 in our hospital (Table 1). Patients
with history of ketoacidosis onset, presence of acute or chronic
infection, possibility of pregnancy or any organ dysfunction were
excluded from this study. Patients were put on an intensive insulin
therapy to maintain normoglycemia until transplantation. Trans-
plantation was performed on average 2.060.9 months following
initial diagnosis as previously reported [6]. Briefly, hematopoietic
stem cells were mobilized with cyclophosphamide (2.0 g/m
2) and
granulocyte colony stimulating factor (10 mg/kg per day) and then
collected from peripheral blood by leukapheresis and cryopre-
served. The cells were injected intravenously after conditioning
with cyclophosphamide (200 mg/kg) and rabbit antithymocyte
globulin (4.5 mg/kg). Number of infused CD34
+ cells was
displayed in Table 1. The patients were followed up for glucose
level, HbA1c, C-peptide level, GAD antibody and insulin dosage.
All patients provided written informed consent in accordance with
the protocol approved by the board of medical ethics of Ruijin
Hospital. The board of medical ethics of Ruijin Hospital approved
our study and our study complied with the request of the board of
medical ethics of Ruijin hospital.
Flow cytometry
Blood collections were performed prior to stem cell mobiliza-
tion to establish a baseline, and at six months post-treatment.
Measurements of forward and side scatter were combined with
CD45 to identify lymphocytes and exclude monocytes. Absolute
subpopulations of lymphocyte numbers were calculated based on
the total lymphocyte counts and the percentage of subpopulations
of lymphocyte cells, as identified by flow cytometry using the BD
Multitest panel (BD Biosciences). The fraction of lymphocyte cell
subsets was determined by four-colour FACS analysis using
appropriate surface markers: anti-CD3-PC5; anti-CD45-FITC;
anti-CD4-RD1; anti-CD8-ECD and anti-CD45-PC5; anti-CD19-
FITC; anti-CD20-FITC and anti-CD45-PC5; anti-CD16-PE;
anti-56-PE; anti-CD3-FITC (Beckman, UK).
Microarray experiment
Comparative microarray profiling was performed pre-treatment
and at six months post-transplantation. PBMC was isolated within
six hours by Lymphoprep
Tm gradient purification according to the
manufacturer’s instructions (Axis-Shield PoC AS, Oslo, Norway)
and stored in liquid nitrogen until use. Total RNA was isolated by
RNAEasy (Qiagen, Valencia, CA) and RIN values assessed using
an Agilent 2100 Bioanalyzer. cDNA synthesis, hybridization, and
staining were performed as specified by Affymetrix Human
Genome U133 Plus 2.0 Arrays, using an automated GeneChip
Fluidics Station 450 and Affymetrix Scanner 3000 7 G to generate
CEL files (Santa Clara, CA). All data is MIAME compliant and
the raw data has been deposited in GEO database (GSE29908).
Data analysis
Data analysis was performed with the assistance of Genminix
Informatics Ltd., Co (Shanghai). Gene expression levels were
normalized using the robust multiarray average (RMA) procedure
and then were normalized using the median normalization
method for differential genes. Differentially expressed genes (pre-
treatment vs post-treatment) were selected by software R and
filtered by random variance model (RVM) [9] paired T test when
p,0.05 and FDR,0.05. Pathway analysis was performed using
the BioCarta database (www.biocarta.com) and computed by
Fisher’s exact test and Chi-square test to identify pathways
modified by AHST when p,0.05 and FDR,0.05. For the
differential co-expression network [10], we first created a gene-set
by combining the differently expressed genes showing a response
to AHST in the IF and ID groups. Secondly, we merged the six
samples in IF group into three based on the similarity in expression
profile of individual sample. Co-expression networks were
generated by calculating the coefficient correlation of the
combined gene-set in the four data sets: pre-treatment in IF,
post-treatment in IF, pre-treatment in ID and post-treatment in ID
group (Figure S1). We defined a connectivity measure (K) for each
gene based on its Pearson correlation with all of the other genes in
each network and divided by the maximum network connectivity.
The differential connectivity of pre-treatment and post-treatment
was defined as DiffK=K(post-treatment)-K(pre-treatment). The
‘hub gene’ was identified when DiffK.0.2 or ,20.2 and p,0.05.
Statistical analysis
The logarithm (base e) of GADA was proposed when statistical
analysis was performed. A paired T test was used to compare (per
patient) pre-treatment and post-treatment data using SPSS statistics
17.0. Significant differences between patient groups were assessed
with the Mann-Whitney test (SPSS statistics 17.0). All P values were
2-sided and exact test; statistical significance was set at p=0.05.
Results
Evaluation of clinical response at 12-month follow-up
revealed two categories
Within 12-month follow-up period, six patients (1, 2, 3, 4, 6 and
9) became insulin free (defined as IF group), while the remaining
patients (5, 7, and 8) still required insulin injection (defined as ID
group), although with reduced dosage (average of 0.38 IU/kg/
day) (Table 1). For the IF group, the C-peptide production
represented by fasting C-peptide, Cmax and AUCC was
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p,0.05, compared with pre-treatment), while no significant
changes were detected in ID group. Furthermore, IF groups
showed significant higher levels of fasting C-peptide, Cmax and
AUCC at different follow-up time points after transplantation
(Figure 1A, B and C). These differences in C-peptide production
were not apparent prior to transplantation (Table 1). The HbA1c
level decreased significantly one month after transplantation and
maintained at less than 7% during 12 months follow-up in all
patients except patient 7 in ID group showed HbA1c level at 8.3%
at 12 months with poor glucose control (Figure 1E).
At six months follow-up, eight of the nine patients showed
declined GADA titers and increased GADA wasonlynoticed inone
patient from the IF group. However, there was no significant
difference pre-treatment and post-transplantation. Interestingly, the
GADA level was significantly decreased in ID group comparing to
IF group at six months follow-up (P=0.036) (Figure 1D).
In comparing the pretreatment parameters of the two groups
there were no significant differences related to age, BMI, duration
time, glucose levels, HbA1c or GAD antibody (Table 1).
As to the side effects, we noted bacteria and fungus infections
only in conditioning time and shortly after AHST treatment:
staphylococcus and streptococcus infection in patient 6, 7, 8 and 9;
vulvovaginal candidiasis in patient 9. No virus infection was
observed. No late complications, such as late infection (.100
days), autoimmune disease and dysfunction of gonad axis have
been noticed until 12 months follow-up.
Lymphocyte subpopulation was distributed
independently of insulin use
To examine if acute response in lymphocytes was able to
identify a potential mechanism of therapeutic response, we
profiled the lymphocyte subpopulation and immune reconstitution
in patients at six months. As shown in Table 2, both groups
showed declined CD3
+CD4
+ T cell populations and recovered
CD19, CD20 as well as NK cell counts (CD3
2CD16
+CD56
+)a t6 -
month follow-up; CD19 and CD20 positive lymphocyte tended to
increase in IF group and decrease in ID group; for CD3
+CD8
+ T
cell, the trend of decline exists in both groups although no statistic
significance (p=0.12) was found, which should be explained
carefully because of the small sample size. No significant
differences in cell populations were observed between the IF and
ID groups either pre-treatment or six months post-treatment
(Table 3).
An array-based genomic study revealed transcriptional
events associated with insulin dependence
Given the limited signature that can be obtained by lymphocyte
population profiling we opted to additionally perform transcrip-
tome analysis. For both the responding (IF) and non-responding
(ID) patient groups, we observed that most immune-related genes
were up-regulated (Table S1) and the number of significantly
regulated genes was greater in the IF group compared to ID group
(Figure 2). A majority of the pathway categories were observed in
both IF and ID groups, but group-specific pathways also existed.
These findings are summarized in Table S2, which shows the top
20 pathways commonly and differentially modified in each group.
Top two pathway categories commonly identified in the two
groups included (1) selective expression of chemokine receptors
during T-cell polarization and (2) IL12 and Stat4 dependent
signaling pathway in Th1 development. These two pathways
indicated that T cell was differentiated to Th1 subset after AHST.
Of interest, the IFN-c signaling pathway was the top ranked
differential pathway in the ID group. Co-expression network
analysis was performed based on combined differential genes in
pre-treatment and post-treatment of IF and ID group respectively.
Table 1. Pretreatment and follow-up variables of patients with type 1 diabetic mellitus undergoing autologous nonmyeloablative
hematopoietic stem cell transplantation.
Pre-treatment Insulin Dose (IU/Kg/day) C-peptide
g
Case/
sex
Age
(Y)
BMI
(kg/m
2)
Stem cell Infusion
(CD34
+*10
6/Kg)
Duration
(mo)
a FBG
b PBG
c HbA1c
d GADA
e
pre-
treatment 6 mo 12 mo
pre-
treatment 6 mo 12 mo
1/F 18 17.2 5.95 2.5 6.2 13.8 7.8 410 0.62 0 0 0.11 1.05 1.57
2/M 17 18.7 10.8 1 9.7 9.9 12.9 41.7 0.91 0 0 0.62 1.26 1.25
3/F 21 17.7 17.17 1.5 6.7 8.9 14 153 0.85 0 0 0.62 1.17 1.07
4/M 25 20 8.96 2 7.3 11.3 8.8 289.1 0.41 0.07 0 0.53 1.12 1.58
6/F 15 17.6 24.95 4 6.1 10.5 7.1 2238 0.43 0 0 0.76 0.96 1
9/F 15 16.4 11.49 1.5 5.7 4.6 11.5 4050 0.72 0 0 0.69 1.23 -
Mean 18.5 17.9 13.22 2.1 7 9.8 10.4 864.8 0.66 0.01 0 0.56 1.13 1.29
5/M 15 17.9 7.5 2 4.1 12.1 9.2 60.2 0.61 0.11 0.46 0.4 0.23 0.39
7/M 14 20.6 12.3 1.5 6.5 11.1 11.1 49.1 0.57 0.25 0.5 0.39 0.42 0.58
8/M 18 20.6 11.68 2 4.4 9.4 9.2 146.7 0.56 0.48 0.19 0.46 1.44 0.85
Mean 15.7 19.7 10.49 1.8 5 10.9 9.8 85.3 0.58 0.28 0.38 0.42 0.7 0.61
P
f 0.3 0.083 1 1 0.167 0.714 1 0.167 0.548 0.012 0.012 0.143 0.083 0.036
aDuration referred to duration time from appearance of symptoms of hyperglycemia to treatment of AHST (mo);
bFBG (mmol/L);
cPBG(mmol/L);
dHbA1c (%);
eGADA (U/mL);
fP value, comparison between IF group (patient 1, 2, 3, 4, 6, 9) and ID group (patient 5, 7, 8) using Mann-Whitney test;
gC-peptide (ng/mL); - represent the data did not been acquired.
doi:10.1371/journal.pone.0031887.t001
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network in IF group compared to ID group, shown as a significant
reduced pattern of connectivity post- than pre-transplantation in
IF group. The derivation of co-expression networks based on
coefficient correlations of all differently modified genes identified a
total of 77 and 52 ‘hub’ genes in the IF and ID groups respectively
(Figure 3). The top 20 ‘hub’ genes for each group are summarized
in Table S3.
Discussion
The first nonmyeloablative AHST was performed in a single
patient with severe refractory systemic lupus erythematosus in
Genoa in 1996, with positive outcome [11]. Since then, a wide
spectrum of autoimmune diseases has been treated with AHST.
For T1D, although some studies suggested T1D in a bone marrow
allograft donor might be transmitted to the recipient; other studies
suggested it as secondary responses to GVHD [12]. In addition,
animal studies revealed genetic associated NOD mice and
streptozocin-induced T1D mice can be reversed by allogeneic
[13] and autologous stem cell transplantation [14] respectively.
Since both genetic and environmental risk factors are involved in
human T1D, either type of stem cell transplantation could possibly
benefit T1D patients [15]. In the year of 2007, Dr. Julio C.
Voltarelli’s group reported the encouraging result that 60% of
patients treated with AHST achieved insulin independence and
Figure 1. Time course of fasting C-peptide (A), Cmax (B), AUCC (C), GADA (D) and HbA1c (E) in IF group and ID group respectively.
Black circles, insulin free. Black squares, insulin dependent. X axis represents the time course relative to HSCT. A p,0.05, pre-treatment vs all follow-
up time in IF group; IF vs ID group at 1 month and 12 months post-treatment. B p,0.05, pre-treatment vs all follow-up times in IF group; IF vs ID
group at one month and six months post-treatment. C p,0.05, pre-treatment vs all follow-up times in IF group; IF vs ID group at 12 months post-
treatment. D p=0.036, IF vs ID group at six months post-treatment.
doi:10.1371/journal.pone.0031887.g001
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reported here were similar, with 67% of patients remaining non-
insulin dependent at the 12-month follow-up (Table 1) and the
remarkable increase of C-peptide production suggesting improved
b cell function. Although prolonged follow-up is needed, our
findings clearly provide additional evidence that nonmyeloablative
AHST offers effectiveness in newly diagnosed T1D, especially
preservation of b cell function. However, a differential clinical
response was identified as three patients were still on an
intermediate dose of insulin therapy although the pre-treatment
levels of age, BMI, duration time, glucose levels, HbA1c, GADA
and C-peptide were similar in the two groups.
Consist with Dr. Julio C. Voltarelli’s report [6], the patients in
our study maintained persistence of anti-GAD antibodies,
suggesting that the conditioning regiment did not fully ablate
autoreactive B-cell clones. The fact that GADA was significantly
decreased in ID group than IF group confirms that the magnitude
of the humoral response and GADA titers are not predictive of
beta cell reserve or clinical response [16].
Infection in conditioning period and late infection are a major
problem contributing to significant mortality and disease relapse in
hematopoietic system malignancies after AHST. In our study, two
patients in each group had bacteria or fungus infection during
conditioning period while no patient presented late complications,
suggesting lack of association of infections with clinical response
and AHST may serve as a safe strategy to manage T1D patients.
The pathogenesis of T1D is known to involve a complex
interaction of immune cells including CD4
+ and CD8
+ T cells,
NK cells, B cells, and etc [2], raising the question of how the
different patterns of immune reconstitution might contribute to
recovery of b cell function. In SLE and systemic sclerosis (SS),
AHST induced immunologic self-tolerance by both depletion of
autoreactive T cells and restoration of immune regulatory network
mediated by CD4
+CD25
+T cell; the T cell subpopulation
recovered from immune-suppression until approximately one year
[17,18]. In our study, both groups showed a declined number of
CD3
+CD4
+ and CD3
+CD8
+T cell population at 6-month follow-
up. Surprisingly, we did not find any significant difference in
lymphocyte subpopulations either at diagnosis or at 6-month
follow-up even when we evaluated the lymphocyte subpopulation
in an independent set of data (Table S5). However, we cannot rule
out mechanisms involving lymphocyte subpopulation function that
occur independent of total cell number. For example, the average
numbers of B cell tended to increase in IF group and decrease in
ID group (Table 2 and Table S4). At diagnosis, although the
number of CD19 and CD20 positive lymphocyte did not differ in
the two groups, but ID group tended to show a higher number.
Therefore, with our data it is difficult to exclude the roles of B
Table 2. Phenotype analysis of lymphocyte populations after hematopoieticstem cell transplantation (AHST)
a.
IF group ID group
Lymphocyte population At diagnosis
six months
after AHST P value
b At diagnosis
six months
after AHST P value
c
Total 18466899 9266172 0.05 21796344 11066223 0.02
CD3+ 15666769 5796120 0.17 16256240 6446168 0.01
CD3+CD4+ 8736365 186628 0.009 8456171 230674 0.03
CD3+CD8+ 5416372 3186131 0.12 6546124 353692 0.004
CD19+ 2046134 2526115 0.63 323639 287658 0.58
CD20+ 2066143 3756302 0.28 335639 261672 0.33
CD32CD16+CD56+ 54647 77676 0.54 146695 165660 0.48
aValues are the mean6SD counts/mL. See Results for description of groups;
bP value between at diagnosis and six months in IF group using paired T test;
cP value between at diagnosis and six months in ID group using paired T test.
doi:10.1371/journal.pone.0031887.t002
Table 3. Phenotype analysis of lymphocyte subpopulations at diagnosis and six months after AHST
a.
At diagnosis six months after AHST
Lymphocyte population IF ID P value
b IF ID P value
c
Total 18466899 21796344 0.99 9266172 11066223 0.38
CD3+ 15666769 16256240 0.91 5796120 6446168 0.71
CD3+CD4+ 8736365 8456171 0.92 186628 230674 0.25
CD3+CD8+ 5416372 6546124 0.91 3186131 353692 0.70
CD19 2046134 323639 0.19 2526115 287658 0.61
CD20 2066143 335639 0.16 3756302 261672 0.57
CD32CD16+CD56+ 54647 146695 0.10 77676 165660 0.11
aValues are the mean6SD counts/mL. See Results for description of groups;
bP value at diagnosis between IF group and ID group using Mann-Whitney test;
cP value at six months after AHST between IF group and ID group using Mann-Whitney test.
doi:10.1371/journal.pone.0031887.t003
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patients.
Gene expression changes in the circulating cells were associated
with T1D [19]. We therefore performed extensive transcriptome
analysis in PBMCs. As expected, we found common transcripts
and pathways grouping all patients independent of their response
to treatment, demonstrating a similar mechanistic response to
transplantation. Some fraction of these changes might be directly
related to a favorable response to treatment. Interestingly, the
majority of the immune-related genes were upregulated after
transplantation. That may be explained by two possibilities:
activation of immune regulatory component or expansion of non-
specific immune response or both [17,19]. In our study, no
transcription factors for immune regulatory component such as
FoxP3 or cytokine IL10 were significantly changed. This led to
speculation that it might be the elimination of the islet targeting
autoreactive T cells that improved b cell function. Surely further
analysis was required. Indeed, in the IF group we observed more
transcriptional modifications, indicating higher sensitivity to
AHST.
Top two pathway categories commonly identified in both
groups included (1) selective expression of chemokine receptors
during T-cell polarization and (2) IL12 and Stat4 dependent
signaling pathway in Th1 development. These two pathways
indicated that T cell was differentiated to Th1 subset after AHST,
which was consistent with a recent study displaying predominant
reconstitution of Th1 CD4+T after autologous CD34+ stem cell
transplantation in patients with systemic sclerosis [20]. T cell
regenerated from thymus after AHST was reported to present a
new and diverse TCR repertoire [17]. We therefore speculate that
the reconstituted Th1 CD4+T cell in our study may be not
reactive to insulin b cell. In the ID group the IFN gamma signaling
pathway was found to be the most significantly modified pathway.
Given the pro-inflammatory role of IFN-c, it is possible that
activation of this pathway may be responsible for the less favorable
outcome in ID group [21].
Additionally, the highly connected ‘hub’ genes, which are
thought to play an important role in organizing the behavior of
biological modules [22,23], were found to be associated with
insulin dependence. Two of these ‘hub’ genes are worth noting.
The first is a T1D susceptible gene, TCF7 [24], which was shown
to be a critical transcriptional regulator for memory CD8
+T cell
differentiation and longevity [25]. In our study, AHST markedly
decreased the number of connections to TCF7 in IF group,
indicating a potential memory T cell decline and naive T cell
regeneration after AHST. This is an observation consistent with
previous findings [17,26]. The second involves GZMA, the gene
encoding Granzyme A. GZMA connections were found to be
markedly increased in the ID group. Granzyme A can promote
production of inflammatory cytokines from antigen-presenting
cells [27] and induce caspase-independent mitochondrial cell
death [28]. Granzyme A is expressed in and surrounding the islets
during the development of spontaneous diabetes mellitus in the
non-obese diabetic mouse [29]. GZMA up-regulation in our study
might contribute to insulin resuming in ID group but certainly
requires further investigation. Regardless, the distinct transcrip-
tional events suggest different patterns of immune dysregulation
exist in T1D patients.
In summary, we evaluated the clinical and molecular response
of nonmyeloablative AHST in nine newly diagnosed T1D
patients. AHST improved islet cell function, possibly by
elimination of the islet specific autoreactive T cells. T1D patients
Figure 2. Workflow of the genomic expression profiling of the
PMBC in patients with type 1 diabetes. Differentially expressed
genes (pre-treatment vs post-treatment) meet the criterion p,0.05 and
FDR,0.05. Up, genes with higher expression after AHST. Down, genes
with lower expression after AHST. Other, genes that were up-regulated
in IF group and down-regulated in ID group.
doi:10.1371/journal.pone.0031887.g002
Figure 3. Sector plots of differential network analysis in IF
group (A) and ID group (B). The difference in connectivity (DiffK) is
plotted on the X axis, and p values are plotted on the Y axis. Horizontal
lines indicate a difference in connectivity of 20.2 and 0.2, whereas
vertical lines depict a p value 0.05. Number indicates sector 1–6 and
plots represent genes. The genes ploted in the sector 1 and 3 are
considered as difference in connectivity.
doi:10.1371/journal.pone.0031887.g003
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PLoS ONE | www.plosone.org 6 February 2012 | Volume 7 | Issue 2 | e31887responded differently to AHST, possibly due to distinct transcrip-
tional events in PBMC. Despite the small patient number and
prospective study design, we believe our findings provide
important insights for understanding AHST effectiveness and
possible molecular clues for optimizing AHST management in
T1D patients.
Supporting Information
Figure S1 Co-expression network analysis. Co-expression
networks were generated by calculating the coefficient correlation
of the combined gene-set in the four data sets: pre-treatment in IF
(A), post-treatment in IF (B), pre-treatment in ID (C) and post-
treatment in ID group (D). Red, genes with higher expression than
pretreatment. Green, genes with lower expression than pretreat-
ment. Straight lines represent positive expression correlation
between two genes and plotted line negative correlation. Big
circles represent genes which have more correlation with all of the
other genes in each network, defined ‘hub’ gene.
(DOC)
Table S1 Genes dysregulated by HSCT in IF group and
ID group.
(XLS)
Table S2 Top 20 pathway categories in different
groups.
(DOC)
Table S3 Rewired genes identified by differential
connectivity in IF and ID when treated with AHST.
agene
connectivity in IF group post-treatment;
bgene connectivity in IF
pre-treatment;
cdifference of gene connectivity between pre-
treatment and post-treatment in IF group;
dsignificance of
difference between post-treat and pre-treatment in IF group;
egene connectivity in ID group post-treatment;
fgene connectivity
in ID pre-treatment;
gsignificance of difference between post-treat
and pre-treatment in ID group;
hsignificance of difference between
post-treat and pre-treatment in ID group.
(DOC)
Table S4 Phenotype analysis of lymphocyte subpopula-
tions after hematopoietic stem cell transplantation
(AHST) in another set of patients
a.
aValues are the
mean6SD counts/mL. See Results for description of groups;
bP
value between at diagnosis and 6 months in IF group using paired
T test;
cP value between at diagnosis and 6 months in ID group
using paired T test.
(DOC)
Table S5 Phenotype analysis of lymphocyte subpopula-
tions at diagnosis and six months after AHST in another
set of patients
a.
aValues are the mean6SD counts/mL. See
Results for description of groups;
bP value at diagnosis between IF
group and ID group using Mann-Whitney test;
cP value at six
months after AHST between IF group and ID group using Mann-
Whitney test.
(DOC)
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